Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout

Chinese biotech firm Ascletis first to apply for Hong Kong IPO under new rules 

Hangzhou-based Ascletis says its close to launching the hepatitis C treatment Danoprevir by September 30

Topic |   IPO

TOP PICKS

Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout
READ FULL ARTICLE